Circle Pharma raises $54M as part of Series D while macrocycles heat up

Circle Pharma, a startup working on macrocycles for the “undruggable,” is seeking about $117 million for a Series D.

The company recently closed the first part of the round, reeling in about $54 million from a dozen investors, according to an SEC filing on Wednesday. The Bay Area biotech last disclosed a $66 million Series C in June 2021. Investors included The Column Group, Nextech Invest, Pandect Bioventures and Eli Lilly. Its website also lists Pfizer as an investor.

The preclinical biotech is developing cyclin A/B, D and E inhibitors for various solid tumors. Earlier this week, Circle said it requested its first clinical trial clearance in the US, aiming to test its experimental oral medicine CID-078 in various tumor types. It gathered preclinical data in small cell lung, triple-negative breast, ER-low breast and HR-positive breast cancers.

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks